Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Other Non-Current Liabilities (2020 - 2025)

Tarsus Pharmaceuticals has reported Other Non-Current Liabilities over the past 6 years, most recently at $10.6 million for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $10.6 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $10.6 million (changed N/A YoY), and the annual figure for FY2025 was $10.6 million, changed.
  • Other Non-Current Liabilities for Q4 2025 was $10.6 million at Tarsus Pharmaceuticals, up from $10.1 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for TARS hit a ceiling of $10.6 million in Q4 2025 and a floor of $40000.0 in Q1 2023.
  • Median Other Non-Current Liabilities over the past 5 years was $905000.0 (2021), compared with a mean of $2.0 million.
  • Biggest five-year swings in Other Non-Current Liabilities: plummeted 91.94% in 2023 and later skyrocketed 3915.0% in 2024.
  • Tarsus Pharmaceuticals' Other Non-Current Liabilities stood at $699000.0 in 2021, then tumbled by 85.69% to $100000.0 in 2022, then skyrocketed by 1648.0% to $1.7 million in 2023, then fell by 29.06% to $1.2 million in 2024, then surged by 754.76% to $10.6 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $10.6 million (Q4 2025), $10.1 million (Q3 2025), and $1.2 million (Q3 2024) per Business Quant data.